Virometix
Lilli Stergiou has 20 years of research and development experience in multiple fields including all areas of interest to Virometix – vaccines, infectious diseases, and oncology. She has a PhD in Molecular Biology and Genetics from the University of Zurich. Lilli joins Virometix from Redbiotec AG, where she was CSO, headed the HSV-2 Therapeutic Vaccine Program and built a pipeline based on Live Biotherapeutics for applications in oncology.
This person is not in any offices